Tekla Life Sciences Investors
HQL · NYSE
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.3% | 120.1% | 23.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 46.4% | 82.6% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 99.1% | 100.6% | 126.8% | -318.9% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 99.1% | 98.4% | 56.8% | -328.3% |
| EPS Diluted | 0 | 3.04 | 0.79 | -4.07 |
| % Growth | -100% | 284.8% | 119.4% | – |
| Operating Cash Flow | – | – | $0 | $0 |
| Capital Expenditures | – | – | $0 | $0 |
| Free Cash Flow | – | – | $0 | $0 |